8-K: Reviva posts FY25 loss, plans second Phase 3

Reviva reported a narrower 2025 net loss, raised $10M in March 2026, and will run a second Phase 3 trial for brilaroxazine before an NDA filing for schizophrenia.

Summary

• FDA provided written guidance recommending a second Phase 3 trial (RECOVER-2) to generate additional efficacy and safety data before an NDA submission for brilaroxazine in schizophrenia.
• RECOVER-2 initiation is planned for mid-2026; trial-related activities begin in Q2-2026 with U.S. patient enrollment planned for Q3-2026.
• Long-term (1-year) open-label data in schizophrenia (N=446; completers N=159) showed sustained efficacy across multiple domains, <1% relapse on treatment, minimal motor side effects, ~1.5 kg weight gain over 52 weeks, favorable lipid profile, stable blood sugar, reduced prolactin to normal/near normal, and no clinically significant cardiac, GI, or liver injury signals.
• Completed NDA-enabling carcinogenicity studies and cGMP manufacturing of registration batches for drug substance and product.
• FY2025 net loss was $19.864902 million ($5.48 per share) versus FY2024 net loss of $29.918802 million ($17.73 per share).
• Cash and cash equivalents were $14.438792 million at December 31, 2025 (vs. $13.476331 million at December 31, 2024).
• Public equity offerings: $10.0M (June 2025), $9.0M (September 2025), and $10.0M (March 2026, gross proceeds).
• Post-March 2026 offering, cash and cash equivalents are approximately $23 million (unaudited), expected to fund operations into Q1-2027.
• A 1-for-20 reverse stock split was effected on March 9, 2026; all share and per share figures are retrospectively adjusted.
• European patent EP3749324 granted in November 2025 covering brilaroxazine for pulmonary fibrosis (including IPF).

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as moderately positive: clear FDA guidance and strong long-term safety/efficacy signals are constructive, though the added Phase 3 requirement extends timelines and preserves financing risk.

Positives

• Clear FDA guidance and path forward: second registrational Phase 3 (RECOVER-2) prior to NDA.
• Robust 1-year OLE outcomes among completers (N=159): sustained PANSS total improvement (~18.1), positive symptoms (-5.0), negative symptoms (-4.4), general psychopathology (-8.7), PSP (+11.3), CGI-S (-0.8; 1-point improvement in 78% of patients).
• <1% relapse on treatment over 1 year and minimal motor side effects (no clinically meaningful changes in akathisia/extrapyramidal scales).
• Metabolic and hormonal profile favorable: ~1.5 kg weight gain over 52 weeks (non–dose-dependent), improved lipids, stable blood sugar, reduced prolactin to normal/near normal, improved thyroid and sexual function.
• No clinically significant cardiac or GI adverse events and no drug-induced liver injury reported in the program.
• NDA-enabling carcinogenicity studies and cGMP registration batches (API and drug product) completed, de-risking CMC and nonclinical components.
• FY2025 net loss narrowed to $19.9M from $29.9M in FY2024; current liabilities reduced to $7.276M from $14.602M YoY, strengthening the balance sheet.
• Approximately $23M cash post-March 2026 raise, with runway into Q1-2027, supporting RECOVER-2 initiation.
• IP protection strengthened with EP3749324 grant for pulmonary fibrosis, expanding geographic coverage.

Negatives

• FDA recommendation for a second Phase 3 before NDA extends timelines and requires additional capital and execution risk.
• Company remains loss-making with FY2025 net loss of $19.864902M and accumulated deficit of $184.137952M.
• General and administrative expenses increased to $8.491125M from $7.891521M YoY.
• Ongoing shareholder dilution from multiple equity offerings in 2025 and 2026 and a 1-for-20 reverse stock split on March 9, 2026.

Risks

• A second Phase 3 trial is required prior to NDA submission for brilaroxazine in schizophrenia, adding clinical, regulatory, and timeline risk.
• Forward-looking statements highlight risks around clinical and regulatory timelines, trial outcomes, expenses, market opportunity, and the ability to raise sufficient funding.
• Cash runway extends into Q1-2027; additional capital may be required to complete RECOVER-2 and subsequent NDA activities.

Future Outlook

Management plans to initiate the second registrational Phase 3 trial (RECOVER-2) for brilaroxazine in mid-2026 with U.S. enrollment in Q3-2026, continue publishing clinical findings in 2026, pursue partnerships, and use current cash (approx. $23M post-offering) to fund operations into Q1-2027 while preparing for a potential NDA following completion of RECOVER-2.

Management Comments

• “With clear and actionable guidance from the FDA, we are advancing toward initiating our second registrational Phase 3 trial (RECOVER-2) and preparing the data package for supporting a New Drug Application (NDA) for brilaroxazine for the treatment of schizophrenia.” – Laxminarayan Bhat, Ph.D., Founder, President, and CEO
• Management emphasized durable efficacy, consistent safety and tolerability up to one year, and favorable once-daily adherence as key differentiators for brilaroxazine.
• Focus remains on disciplined execution to bring brilaroxazine toward regulatory approval.

Industry Context

StockSavvy.ai notes that the FDA’s recommendation for a second Phase 3 study aligns with typical regulatory expectations for antipsychotics, where two adequate and well-controlled trials are generally sought. Brilaroxazine’s reported long-term tolerability and modest weight gain could be competitive against established atypicals (e.g., olanzapine, risperidone) known for metabolic liabilities, while emerging therapies aim to improve efficacy and side effect profiles in schizophrenia.

Comparison to Industry Standards

• Regulatory pathway: A requirement for two registrational Phase 3 trials prior to NDA is consistent with historic FDA expectations in schizophrenia drug approvals (e.g., multiple late-stage programs from Otsuka/Lundbeck and others).
• Metabolic profile: Reported ~1.5 kg weight gain over 52 weeks compares favorably versus weight gain commonly observed with certain atypicals (e.g., olanzapine), positioning brilaroxazine closer to metabolically friendlier profiles sought in newer agents.
• Extrapyramidal symptoms: No clinically meaningful motor side effects reported contrasts with the movement disorder risks seen in some dopamine antagonists, aligning with best-in-class targets that minimize EPS.
• Adherence: Once-daily oral dosing supports adherence; while long-acting injectables improve adherence via depot formulations (e.g., aripiprazole lauroxil, paliperidone palmitate), a favorable oral profile can be competitive for patients preferring daily dosing.
• Development readiness: Completion of carcinogenicity studies and cGMP registration batches aligns with CMC/nonclinical readiness benchmarks typically required before NDA filing, reducing execution risk outside of pivotal efficacy.

Stakeholder Impact

• Shareholders: Additional equity raises and a 1-for-20 reverse split concentrate shares but also fund pivotal development; dilution remains an overhang.
• Patients: Potential access to a once-daily therapy with favorable tolerability and metabolic profile if approved.
• Employees/Operations: Focus on executing RECOVER-2 and regulatory preparations; funding runway into Q1-2027 supports near-term program continuity.
• Suppliers/CROs: Renewed Phase 3 activity in 2026 may increase operational demand and spend with clinical partners.
• Creditors: Reduced current liabilities improve near-term credit profile.

Next Steps

• Initiate RECOVER-2 registrational Phase 3 trial for schizophrenia in mid-2026.
• Begin RECOVER-2 trial-related activities in Q2-2026 and U.S. enrollment in Q3-2026.
• Publish additional brilaroxazine data in 2026.
• Pursue partnership opportunities to support pipeline development.
• Advance NDA preparations contingent on RECOVER-2 outcomes.

Key Dates

Recommendation

The program’s long-term safety/efficacy signals and FDA-aligned path are encouraging, but the requirement for a second Phase 3 extends timelines and raises execution and funding needs. With cash into Q1-2027 following recent dilution, risk/reward appears balanced pending RECOVER-2 design, enrollment pace, and data.

Keywords

Reviva Pharmaceuticals, brilaroxazine, schizophrenia, RECOVER-2, Phase 3 trial, NDA, antipsychotic, CNS therapeutics, biopharma, clinical trial, reverse stock split, equity offering, cash runway, IPF patent, safety and efficacy